UDK: 615.214.22
D.V. Maltsev 1,2, A.A. Spasov 1,2, M.V. Miroshnikov 1, M.O. Skripka 1, Yu.Yu. Dementenko 1, E.M. Chernikova 1
1 ФГБОУ ВО «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации, кафедра фармакологии и биоинформатики; 2 ГБУ «Волгоградский медицинский научный центр», лаборатория экспериментальной фармакологии
For the substance under the code DAB-21, a pronounced neuropsychotropic potential was previously shown. In this study, possible directions of the influence of the studied substance on basic mediator systems of the CNS are considered. According to the results of the study, a benzodiazepine-like effect of DAB-21 was found in the «Elevated plus maze» test with flumazenil, as well as potentiation of the effects of phenamine, and some serotoninergic effect in the test with 5-GTP, and a weak α2-adrenoblocking effect, revealed using the «Clofelinic hypothermia» test. There was also a D2-activating effect according to the haloperidol test, a weak M-anticholinergic effect in the arecoline test. Some MAO-inhibitory effect was found, suggested by antagonism with reserpine, as well as the results of the L-DOPA test. The compound did not interact with nicotine and apomorphine. The neurotransmitter profile of the compound DAB-21 is of interest for further study and clarification of the mechanism of action of the substance.
DAB-21, new compounds, anxiolysis, depression, in vivo, GABA, 5-HTP, phenamine, L-DOPA.
Мальцев Дмитрий Васильевич – к. б. н., доцент кафедры фармакологии и биоинформатики, Волгоградский государственный медицинский университет, e-mail: maltsevdmitriy@rambler.ru